Strategy

With the patient voice growing louder in all aspects of the drug development and commercialization journey, Pharm Exec examines some of the current industry thinking on the evolving pharma-patient relationship.

Jackie DeAngelis outlines three common mistakes that hinder access attainment when launching a new drug.

For pharma, diagnosing what ails or strengthens performance in this critical corporate discipline may help reshape business prognosis.

Study examines why a pharma brand’s early sales are not a trusted predictor for total lifetime value-it’s about driving waves of growth.

Pharm Exec's Editorial Advisory Board member, Peter Young, cover a summary of the strategic issues facing the biopharma industry, but goes on to tell the story of what happened last year and this first quarter in terms of the stock market, M&A and financing (including IPOs) activity, where it is headed, and the implications for senior management.

Facing mixed market signals, biotech companies look to rise above the fray in advancing new-wave discoveries to the clinical finish line.

Pharm Exec convenes a panel of biopharma executives responsible for the Latin America business to discuss investment, market access, and reimbursement issues in this key and challengingly diverse growth market for the life sciences industry

Global market access analyst Neil Grubert discusses what are likely to be some of the key trends in market access this year and beyond, and the implications for the life sciences industry.

Simon Webster looks at the role of intellectual property (IP) management in protecting pharmaceutical company products.

A new approach to reviving industry collaborations.

The key steps to easing rising complexity and cost factors.

How can Pharma balance the need to access to patient data and still respect patient privacy? One approach is to access patients through third-party online communities, writes Peter Houston.

In a continent marked by stark differences in governance, growth and market potential, the best bets must be pursued off script.

How a Manufacturing Excellence program can deliver competitive advantage to a fast-changing global product mix-at lower cost, and with an unexpected workforce dividend to boot.

However conservative and heavily regulated the drugs business, it too must transform itself to exploit digital opportunities - if only to ward off disruption, says Elvis Paćelat.

Biopharma companies are increasingly leveraging product portfolios to own and dominate strategically important therapeutic areas.

An industry-based working group presents a common standards and definition framework for “Access” competencies in pharma-as a starting point in solving the current shortage of talent and leaders for this widening set of activities.

Loss of exclusivity (LOE) doesn’t have to be the death knell for branded drug revenue streams. The key approaches to preserving meaningful value well into the post-patent-loss future are outlined.

Dan Wetherill offers three priorities for how pharma companies can better use data analytics to engage customers.

Michael Gordon charts the evolution of regulatory operations and suggests how it can spearhead opportunities for innovation in pharma data.

The secret sauce for creating blockbuster brands has always been - and always will be - consistently exceptional team execution. Andy Mehrotra offers the recipe.

For those willing to invest in the right capabilities, offering patient services can give pharma companies a tremendous opportunity.

Payers, providers, patients and pharma companies all want to understand the value of specific treatments – and patient registries can help them do that.

As companies look to raise capital, selling and then leasing back real estate is a tempting option and one that other industries are utilizing, writes Karen Williamson.

The liver disease non-alcoholic steatohepatitis (NASH) has become a priority for the healthcare industry – and, potentially, a multi-billion-dollar market. The race is now to develop the first effective pharmacotherapy to treat it.

Peter Young examines the drivers affecting the biotech industry in 2015, and what to expect in 2016.

Intense regulatory demands, cost pressure, and the need to be ever more efficient has led to an upturn in the use of management consultants in the pharma & biotech sector, writes B.J. Richards.

Several factors are combining to change the definition of what healthcare truly is, and how it will be delivered and experienced in the next few years.

Positioning for success in biopharma requires a self-critical analysis of the risk and rewards among four categories of value differentiation. The key question: How do you define yourself against the competition?

Bruno Villetelle discusses how Japanese companies like Takeda have begun to digitize in order to care for the country's aging population.